Abstract

Background: Antenatal anemia is a risk factor for adverse maternal and fetal outcomes and is prevalent in sub-Saharan Africa. Less than half of antenatal anemia is considered responsive to iron; identifying women in need of iron may help target interventions. Iron absorption is governed by the iron-regulatory hormone hepcidin.Objective: We sought to characterize changes in hepcidin and its associations with indexes of iron stores, erythropoiesis, and inflammation at weeks 14, 20, and 30 of gestation and to assess hepcidin’s diagnostic potential as an index of iron deficiency.Methods: We measured hemoglobin and serum hepcidin, ferritin, soluble transferrin receptor (sTfR), and C-reactive protein (CRP) at 14, 20, and 30 wk of gestation in a cohort of 395 Gambian women recruited to a randomized controlled trial. Associations with hepcidin were measured by using linear regression, and hepcidin’s diagnostic test accuracy [area under the receiver operating characteristic curve (AUCROC), sensitivity, specificity, cutoffs] for iron deficiency at each time point was analyzed.Results: The prevalence of anemia increased from 34.6% at 14 wk of gestation to 50.0% at 20 wk. Hepcidin concentrations declined between study enrollment and 20 wk, whereas ferritin declined between 20 and 30 wk of gestation. The variations in hepcidin explained by ferritin, sTfR, and CRP declined over pregnancy. The AUCROC values for hepcidin to detect iron deficiency (defined as ferritin <15 μg/L) were 0.86, 0.83, and 0.84 at 14, 20, and 30 wk, respectively. Hepcidin was superior to hemoglobin and sTfR as an indicator of iron deficiency.Conclusions: In Gambian pregnant women, hepcidin appears to be a useful diagnostic test for iron deficiency and may enable the identification of cases for whom iron would be beneficial. Hepcidin suppression in the second trimester suggests a window for optimal timing for antenatal iron interventions. Hemoglobin does not effectively identify iron deficiency in pregnancy. This trial was registered at www.isrctn.com as ISRCTN49285450.

Highlights

  • More than 38% of pregnant women worldwide are anemic, with the prevalence greatest in sub-Saharan Africa and parts of Asia [1]

  • We have previously found that hepcidin is a promising tool to identify individuals who might gain the most benefit from iron supplementation and defined putative thresholds that could help define iron deficiency in young children [14] and in women [15]

  • Samples were derived from the Early Nutrition and Immune Development (ENID)9 trial in rural Gambia, which is a randomized trial assessing whether nutritional supplementation to pregnant women and their infants can enhance infant immune development [21]

Read more

Summary

Introduction

More than 38% of pregnant women worldwide are anemic, with the prevalence greatest in sub-Saharan Africa and parts of Asia [1]. Only half of anemia cases in pregnancy worldwide (including only 44% of cases in Africa and 47% of cases in Asia) are attributed to iron deficiency and amenable to iron supplementation [1]. Less than half of antenatal anemia is considered responsive to iron; identifying women in need of iron may help target interventions. Conclusions: In Gambian pregnant women, hepcidin appears to be a useful diagnostic test for iron deficiency and may enable the identification of cases for whom iron would be beneficial. Hemoglobin does not effectively identify iron deficiency in pregnancy This trial was registered at www.isrctn.com as ISRCTN49285450.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call